Soros Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Soros Fund Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,056,000	Closed	-$42.5M	–	272
2026 Q1	$42.5M	Buy	+1,056,000	New	+$22.8M	0.47%	54
2024 Q2	–	Sell	-8,948	Closed	-$526K	–	180
2024 Q1	$526K	Buy	+8,948	New	+$570K	0.01%	188

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Soros Fund Management's APLS Position: Q2 2026 in Review

Soros Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,056,000 shares — an estimated $42.5M sold.

Soros Fund Management first reported a position in APLS in Q1 2024 and held it in 2 quarters. The position peaked at $42.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Soros Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Soros Fund Management sold 1,056,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $42.5M.
Soros Fund Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 2 quarters.
Soros Fund Management's Apellis Pharmaceuticals position peaked at $42.5M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Soros Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.